Posts Tagged ‘COVID-19’
Webinar Equips Pharmacists to Provide Contraception Care During COVID-19
New training program by Birth Control Pharmacist and Provide includes pharmacy best practices to combat stigma and communication guides and online resources to help connect patients with local resources.
Read MoreReproductive Health During COVID: Eliminating FDA’s Burdensome Barriers to Mifepristone
What is Mifepristone? Mifepristone is the primary component in the FDA-approved regimen taken to terminate pregnancies through 10 weeks gestation and is seen as an alternative to a surgical procedure.1 Many patients view this as less invasive, allowing for more privacy and control over a personal situation. The standard oral regimen includes mifepristone 200mg followed…
Read MoreContraception During COVID-19: Pharmacy Best Practices
Pharmacists should not allow postponed or cancelled appointments to keep patients from accessing birth control. It’s important that patients understand how their pharmacy can continue to meet their contraceptive needs during the coronavirus disease 2019 (COVID-19) pandemic. Pharmacists should inform patients that even though clinics and providers’ offices might be closed, their pharmacy is still…
Read MoreClinical Considerations for Contraception During COVID: Extended Duration of IUDs and Implants
During the COVID-19 pandemic and beyond, patients may desire a contactless method of contraception. The subcutaneous (SQ) formulation of depot medroxyprogesterone acetate (DMPA), Depo-SubQ Provera, is an important option to offer patients. This may be of particular interest among patients who currently come in to the pharmacy or go to a clinic for their intramuscular (IM) injection.
Read MoreContraception During COVID: California’s Medi-Cal and FamilyPACT Programs Cover Depo-SubQ Provera
We recently wrote about the importance of offering patients subcutaneous depot medroxyprogesterone acetate (DMPA-SQ) as a contactless form of contraception during the COVID-19 public health emergency. California pharmacists can prescribe DMPA-SQ under statewide protocol upon completing the required training program and obtain payment for the visit for Medi-Cal patients. As of April 9, 2020, California’s…
Read MoreClinical Considerations for Contraception During COVID: Patient Self-Administration
During the COVID-19 pandemic and beyond, patients may desire a contactless method of contraception. The subcutaneous (SQ) formulation of depot medroxyprogesterone acetate (DMPA), Depo-SubQ Provera, is an important option to offer patients. This may be of particular interest among patients who currently come in to the pharmacy or go to a clinic for their intramuscular (IM) injection.
Read More